These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 19000993)

  • 21. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
    Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
    Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
    Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus.
    Sjöwall C; Ernerudh J; Bengtsson AA; Sturfelt G; Skogh T
    J Autoimmun; 2004 Jun; 22(4):315-23. PubMed ID: 15120755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations.
    Frostegård J; Svenungsson E; Wu R; Gunnarsson I; Lundberg IE; Klareskog L; Hörkkö S; Witztum JL
    Arthritis Rheum; 2005 Jan; 52(1):192-200. PubMed ID: 15641060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of biological markers of activity of systemic lupus erythematosus with levels of anti-oxidized low-density lipoprotein antibodies.
    Gómez-Zumaquero JM; Tinahones FJ; De Ramón E; Camps M; Garrido L; Soriguer FJ
    Rheumatology (Oxford); 2004 Apr; 43(4):510-3. PubMed ID: 14872100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study.
    Dhir V; Singh AP; Aggarwal A; Naik S; Misra R
    Lupus; 2009 Aug; 18(9):785-91. PubMed ID: 19578102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of walnut-enriched meat on the relationship between VCAM, ICAM, and LTB4 levels and PON-1 activity in ApoA4 360 and PON-1 allele carriers at increased cardiovascular risk.
    Canales A; Sánchez-Muniz FJ; Bastida S; Librelotto J; Nus M; Corella D; Guillen M; Benedi J
    Eur J Clin Nutr; 2011 Jun; 65(6):703-10. PubMed ID: 21407247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus.
    Chung CP; Oeser A; Solus J; Avalos I; Gebretsadik T; Shintani A; Linton MF; Fazio S; Stein CM
    J Rheumatol; 2007 Sep; 34(9):1849-54. PubMed ID: 17659756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus.
    Su Y; Jia RL; Han L; Li ZG
    Clin Immunol; 2007 Jan; 122(1):115-20. PubMed ID: 17085075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody clustering helps refine lupus prognosis.
    Kessel A; Rosner I; Halasz K; Grushko G; Shoenfeld Y; Paran D; Toubi E
    Semin Arthritis Rheum; 2009 Aug; 39(1):66-70. PubMed ID: 18538829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
    Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC
    Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus.
    López P; Rodríguez-Carrio J; Martínez-Zapico A; Pérez-Álvarez ÁI; López-Mejías R; Benavente L; Mozo L; Caminal-Montero L; González-Gay MA; Suárez A
    Thromb Haemost; 2017 Nov; 117(11):2194-2206. PubMed ID: 29044294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices.
    Szekanecz E; Szucs G; Szekanecz Z; Tarr T; Antal-Szalmás P; Szamosi S; Szántó J; Kiss E
    J Autoimmun; 2008 Dec; 31(4):372-6. PubMed ID: 18926664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus.
    Hellmich B; Csernok E; Schatz H; Gross WL; Schnabel A
    Arthritis Rheum; 2002 Sep; 46(9):2384-91. PubMed ID: 12355486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new.
    Elwy MA; Galal ZA; Hasan HE
    East Mediterr Health J; 2010 Aug; 16(8):893-900. PubMed ID: 21469572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of atherosclerotic risk factors and endothelial function in children and young adults with pediatric-onset systemic lupus erythematosus.
    Soep JB; Mietus-Snyder M; Malloy MJ; Witztum JL; von Scheven E
    Arthritis Rheum; 2004 Jun; 51(3):451-7. PubMed ID: 15188333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus.
    Haddouk S; Marzouk S; Jallouli M; Fourati H; Frigui M; Hmida YB; Koubaa F; Sellami W; Baklouti S; Hachicha J; Bahloul Z; Masmoudi H
    Rheumatology (Oxford); 2009 Aug; 48(8):953-7. PubMed ID: 19502474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
    Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity.
    Leaños-Miranda A; Pascoe-Lira D; Chávez-Rueda KA; Blanco-Favela F
    J Rheumatol; 2001 Jul; 28(7):1546-53. PubMed ID: 11469460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
    Lakshman MR; Gottipati CS; Narasimhan SJ; Munoz J; Marmillot P; Nylen ES
    Metabolism; 2006 Sep; 55(9):1201-6. PubMed ID: 16919539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.